To read the full article sign up for free or sign in.

Carsgen out-licenses China rights to Huadong for BCMA CAR T for $152M

Jan. 17, 2023

CAR T specialist Carsgen Therapeutics Holdings Ltd. out-licensed commercial rights for its B-cell maturation antigen (BCMA) CAR T therapy, CT-053, in mainland China to Huadong Medicine Co Ltd. in a deal worth up to $152 million.

BioWorld BioWorld Asia Deals and M&A License Asia-Pacific China

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 3, 2022.

Setpoint Medical - vagus nerve stimulation device

Setpoint Medical lands up to $145M to advance RA implant

BioWorld MedTech

Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...

CFIUS singles out mergers with Chinese companies as potential national security threats

BioWorld

Proposed mergers with Chinese companies will likely be subject to increased scrutiny from the Committee on Foreign Investment in the United States (CFIUS) as...

Upgrade your daily dose of biopharma and medtech news

Carsgen out-licenses China rights to Huadong for BCMA CAR T for $152M